Literature DB >> 6386074

The role of post-operative radiotherapy in the treatment of operable breast cancer.

G F Beadle, J R Harris.   

Abstract

In current practice, the management of early stage breast cancer involves a multidisciplinary cooperation among surgeons, radiation therapists, and medical oncologists. The goals of local treatment in this setting are to secure tumor control and to identify patients who are to be treated with adjuvant systemic therapy. For patients treated by mastectomy, the value of post-operative radiotherapy in primary treatment remains controversial. In this review, we examine the evolution of treatment philosophies for operable breast cancer and the results from recent clinical studies in an attempt to assess the current role of post-operative radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6386074     DOI: 10.1007/bf01806481

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  29 in total

1.  Locally recurrent carcinoma of the breast. Results of radiation therapy.

Authors:  F C Chu; F J Lin; J H Kim; S H Huh; C J Garmatis
Journal:  Cancer       Date:  1976-06       Impact factor: 6.860

2.  Results in patients with breast cancer treated by radical mastectomy and postoperative irradiation with no adjuvant chemotherapy.

Authors:  N D Tapley; W J Spanos; G H Fletcher; E D Montague; S Schell; M J Oswald
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

3.  Adjuvant radiotherapy in operable breast cancer: correlation between dose in internal mammary nodes and prognosis.

Authors:  L E Strender; A Wallgren; J Arndt; O Arner; J Bergström; B Blomstedt; P O Granberg; B Nilsson; L Räf; C Silfverswärd
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-10       Impact factor: 7.038

4.  Surgical adjuvant chemotherapy: results with one short course with cyclophosphamide after mastectomy for breast cancer.

Authors:  R Nissen-Meyer; K Kjellgren; K Malmio; B Månsson; T Norin
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

5.  Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy.

Authors:  B Fisher; N Slack; D Katrych; N Wolmark
Journal:  Surg Gynecol Obstet       Date:  1975-04

6.  The impact of primary irradiation treatment of localized breast cancer on the ability to administer systemic adjuvant chemotherapy.

Authors:  M E Lippman; A S Lichter; B K Edwards; C R Gorrell; T d'Angelo; E V DeMoss
Journal:  J Clin Oncol       Date:  1984-01       Impact factor: 44.544

7.  Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience.

Authors:  E Velez-Garcia; M Moore; C L Vogel; V Marcial; A Ketcham; A Bartolucci; C Liu; R Smalley
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

8.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

9.  The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology--an overview of findings.

Authors:  B Fisher; C Redmond; E R Fisher
Journal:  Cancer       Date:  1980-08-15       Impact factor: 6.860

10.  Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients.

Authors:  P Valagussa; G Bonadonna; U Veronesi
Journal:  Cancer       Date:  1978-03       Impact factor: 6.860

View more
  1 in total

1.  A randomized trial of chemotherapy (L-PAM vs CMF) and irradiation for node positive breast cancer. Eleven year follow-up of a Piedmont Oncology Association trial.

Authors:  H B Muss; M R Cooper; J K Brockschmidt; C Ferree; F Richards; D R White; D V Jackson; C L Spurr
Journal:  Breast Cancer Res Treat       Date:  1991-10       Impact factor: 4.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.